US FDA expands use of Bristol Myers' cancer therapy-March 2024-www.financetom.com

US FDA expands use of Bristol Myers' cancer therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA expands use of Bristol Myers' cancer therapy

Mar 14, 2024 6:58 PM

March 14 (Reuters) - The U.S. Food and Drug

Administration on Thursday expanded the use of Bristol Myers

Squibb's ( BMY ) cell therapy, Breyanzi, for a type of

slow-growing blood cancer, marking the second approval for the

treatment.

(Reporting by Bhanvi Satija, Puyaan Singh and Mrinmay Dey in

Bengaluru; Editing by Shailesh Kuber and Mrigank Dhaniwala)

Previous page： Market Chatter: Thermo Fisher Nearing $10 Billion Takeover of Clario Next page： Amazon's AWS to Invest Over $5 Billion in South Korea

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Thermo Fisher Nearing $10 Billion Takeover of Clario

Oct 29, 2025

06:06 AM EDT, 10/29/2025 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) is close to acquiring drug trial software maker Clario in an all-cash deal that could value the healthcare technology group at about $10 billion, the Financial Times reported Tuesday, citing people familiar with the matter. A deal could be announced as early as Wednesday, two sources told...

Amazon's AWS to Invest Over $5 Billion in South Korea

Oct 29, 2025

06:06 AM EDT, 10/29/2025 (MT Newswires) -- Amazon.com's ( AMZN ) cloud computing arm, Amazon Web Services, will invest more than $5 billion to build artificial intelligence data centers in South Korea's Incheon and Gyeonggi regions by 2031, South Korea's presidential office said on Wednesday. The new investment follows AWS's earlier commitment in Ulsan and marks the largest greenfield investment...

Produce distributor Fresh Del Monte Q3 revenue misses analyst expectations

Oct 29, 2025

(Corrects EPS in Key Details table to -$0.61, from $0.61) Overview * Fresh Del Monte Q3 revenue misses analyst expectations * Company reports Q3 net loss of $29.1 mln due to higher costs and impairments * Company to divest Mann Packing to focus on higher-margin products Outlook * Fresh Del Monte plans to divest Mann Packing in Q4 2025 *...

Renasant Q3 Adjusted Earnings, Revenue Rise; Shares Fall

Oct 29, 2025

06:07 AM EDT, 10/29/2025 (MT Newswires) -- Renasant ( RNST ) reported Q3 adjusted earnings late Tuesday of $0.77 per diluted share, up from $0.70 a year earlier. Analysts polled by FactSet expected $0.78. Revenue for the quarter ended Sept. 30, expressed as the sum of net interest income and noninterest income, was $269.5 million, up from $220.3 million a...